CTRCD is one of the most feared side effects of cancer treatment, occurring in approximately 10% of patients.
A new study aims to validate cardiotoxicity risk assessment guidelines.
โก๏ธ https://t.co/TUdjMX1mPj
@Emanrashed01 @PennThalheimer #CardioOncology
Mark your ๐๏ธโOur next #CME, taking place on 10/21-22, will provide a comprehensive update on the management of #heartfailure focusing on the recently updated ACC/AHA HF Management Guidelines.
Learn more & register โฌ๏ธ https://t.co/N6quvkQLUy
#MedEd#CardioTwitter